Clinical Trials
61
41 active
Approvals
6
Total approvals
Agencies
2
Regulatory bodies
Founded
1986
Active, not recruiting
40
65.6%
Completed
5
8.2%
Not yet recruiting
1
1.6%
Recruiting
15
24.6%
- A phase 2 randomized trial of 130 patients found that trabectedin plus olaparib achieved a 32% six-month progression-free survival rate compared to 28% with trabectedin alone in advanced soft tissue sarcoma. - The combination showed particular benefit in patients with PARP1 expression and uterine leiomyosarcoma, with 40% of uterine leiomyosarcoma patients remaining progression-free at 12 months. - While the overall benefit was marginal in the all-comers population, the study identified PARP1 expression as a promising biomarker for selecting patients who may benefit from this combination therapy.
- A new comprehensive report on Ewing Sarcoma clinical trials provides critical insights into global research trends, trial distribution, and enrollment patterns across G7 and E7 countries. - The analysis highlights key pharmaceutical players in Ewing Sarcoma research, including Bristol-Myers Squibb, Merck, Pfizer, and AstraZeneca, offering valuable competitive intelligence for industry stakeholders. - The report serves as a strategic resource for identifying investment opportunities, optimal trial locations, and understanding success rates through comparative analysis of completed versus terminated trials.
